The Experts below are selected from a list of 117 Experts worldwide ranked by ideXlab platform
Yuji Kuge - One of the best experts on this subject based on the ideXlab platform.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors. We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-18F-fluorobenzoyl)norBiotinamide (18F-FBB), a radiolabeled Biotin Derivative, for performing a biodistribution study and for PET imaging. The tumoral 18F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal. 18F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral 18F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing 18F-FBB accumulation corresponded to HIF-1α-positive areas. Pretargeting with POS and 18F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:Purpose We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors.
-
synthesis and biological evaluation of a novel 18f labeled Biotin Derivative for strept avidin based pretargeted diagnosis
The Journal of Nuclear Medicine, 2008Co-Authors: Masashi Ueda, Takashi Kudo, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Hideo SajiAbstract:1259 Objectives: (Strept)avidin-Biotin based multistep targeting holds great promise for the detection and therapy of cancer. We have generated a streptavidin analogue, PCOS, for tumor hypoxia imaging (JNM48, Suppl.2, 21P). A radiolabeled Biotin Derivative is necessary to image with PCOS. For this purpose, we synthesized (4-[18F]fluorobenzoyl)norBiotinamide (18F-FBB), a novel 18F-labeled Biotin, and evaluated its suitability for pretargeted imaging. Methods: Radiosynthesis of 18F-FBB was performed by the conjugation of norBiotinamine and N-succinimidyl-4-[18F]fluorobenzoate. We prepared PCOS and the binding of 18F-FBB to avidin or PCOS was assessed. The stability of 18F-FBB in mouse plasma was checked by paper chromatography. Biodistribution study and small-animal PET imaging was performed in tumor-bearing mice with PCOS pretargeting 24 h prior to 18F-FBB injection. Results: The decay-corrected radiochemical yield of 18F-FBB was 23% with about 150-min reaction time and the radiochemical purity was greater than 95%. 18F-FBB showed binding affinity to avidin or PCOS. More than 91% of 18F-FBB was stable in mouse plasma for 6 h. 18F-FBB alone cleared quickly from the blood with no evidence of tumor targeting (0.06 %ID/g at 6 h), but when pretargeted with PCOS, tumor uptake increased 67-fold (4.0 %ID/g at 6 h) and the tumor was clearly visualized within 3 h. Conclusions: 18F-FBB exhibited not only an affinity to (strept)avidin in vitro, but it was also capable of binding to pretargeted PCOS and of tumor imaging in vivo. These results suggested that 18F-FBB should be useful for pretargeted imaging with the (strept)avidin-Biotin system.
Shinae Kizakakondoh - One of the best experts on this subject based on the ideXlab platform.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors. We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-18F-fluorobenzoyl)norBiotinamide (18F-FBB), a radiolabeled Biotin Derivative, for performing a biodistribution study and for PET imaging. The tumoral 18F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal. 18F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral 18F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing 18F-FBB accumulation corresponded to HIF-1α-positive areas. Pretargeting with POS and 18F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:Purpose We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors.
Takashi Kudo - One of the best experts on this subject based on the ideXlab platform.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors. We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-18F-fluorobenzoyl)norBiotinamide (18F-FBB), a radiolabeled Biotin Derivative, for performing a biodistribution study and for PET imaging. The tumoral 18F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal. 18F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral 18F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing 18F-FBB accumulation corresponded to HIF-1α-positive areas. Pretargeting with POS and 18F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:Purpose We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors.
-
synthesis and biological evaluation of a novel 18f labeled Biotin Derivative for strept avidin based pretargeted diagnosis
The Journal of Nuclear Medicine, 2008Co-Authors: Masashi Ueda, Takashi Kudo, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Hideo SajiAbstract:1259 Objectives: (Strept)avidin-Biotin based multistep targeting holds great promise for the detection and therapy of cancer. We have generated a streptavidin analogue, PCOS, for tumor hypoxia imaging (JNM48, Suppl.2, 21P). A radiolabeled Biotin Derivative is necessary to image with PCOS. For this purpose, we synthesized (4-[18F]fluorobenzoyl)norBiotinamide (18F-FBB), a novel 18F-labeled Biotin, and evaluated its suitability for pretargeted imaging. Methods: Radiosynthesis of 18F-FBB was performed by the conjugation of norBiotinamine and N-succinimidyl-4-[18F]fluorobenzoate. We prepared PCOS and the binding of 18F-FBB to avidin or PCOS was assessed. The stability of 18F-FBB in mouse plasma was checked by paper chromatography. Biodistribution study and small-animal PET imaging was performed in tumor-bearing mice with PCOS pretargeting 24 h prior to 18F-FBB injection. Results: The decay-corrected radiochemical yield of 18F-FBB was 23% with about 150-min reaction time and the radiochemical purity was greater than 95%. 18F-FBB showed binding affinity to avidin or PCOS. More than 91% of 18F-FBB was stable in mouse plasma for 6 h. 18F-FBB alone cleared quickly from the blood with no evidence of tumor targeting (0.06 %ID/g at 6 h), but when pretargeted with PCOS, tumor uptake increased 67-fold (4.0 %ID/g at 6 h) and the tumor was clearly visualized within 3 h. Conclusions: 18F-FBB exhibited not only an affinity to (strept)avidin in vitro, but it was also capable of binding to pretargeted PCOS and of tumor imaging in vivo. These results suggested that 18F-FBB should be useful for pretargeted imaging with the (strept)avidin-Biotin system.
Masashi Ueda - One of the best experts on this subject based on the ideXlab platform.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors. We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-18F-fluorobenzoyl)norBiotinamide (18F-FBB), a radiolabeled Biotin Derivative, for performing a biodistribution study and for PET imaging. The tumoral 18F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal. 18F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral 18F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing 18F-FBB accumulation corresponded to HIF-1α-positive areas. Pretargeting with POS and 18F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:Purpose We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors.
-
synthesis and biological evaluation of a novel 18f labeled Biotin Derivative for strept avidin based pretargeted diagnosis
The Journal of Nuclear Medicine, 2008Co-Authors: Masashi Ueda, Takashi Kudo, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Hideo SajiAbstract:1259 Objectives: (Strept)avidin-Biotin based multistep targeting holds great promise for the detection and therapy of cancer. We have generated a streptavidin analogue, PCOS, for tumor hypoxia imaging (JNM48, Suppl.2, 21P). A radiolabeled Biotin Derivative is necessary to image with PCOS. For this purpose, we synthesized (4-[18F]fluorobenzoyl)norBiotinamide (18F-FBB), a novel 18F-labeled Biotin, and evaluated its suitability for pretargeted imaging. Methods: Radiosynthesis of 18F-FBB was performed by the conjugation of norBiotinamine and N-succinimidyl-4-[18F]fluorobenzoate. We prepared PCOS and the binding of 18F-FBB to avidin or PCOS was assessed. The stability of 18F-FBB in mouse plasma was checked by paper chromatography. Biodistribution study and small-animal PET imaging was performed in tumor-bearing mice with PCOS pretargeting 24 h prior to 18F-FBB injection. Results: The decay-corrected radiochemical yield of 18F-FBB was 23% with about 150-min reaction time and the radiochemical purity was greater than 95%. 18F-FBB showed binding affinity to avidin or PCOS. More than 91% of 18F-FBB was stable in mouse plasma for 6 h. 18F-FBB alone cleared quickly from the blood with no evidence of tumor targeting (0.06 %ID/g at 6 h), but when pretargeted with PCOS, tumor uptake increased 67-fold (4.0 %ID/g at 6 h) and the tumor was clearly visualized within 3 h. Conclusions: 18F-FBB exhibited not only an affinity to (strept)avidin in vitro, but it was also capable of binding to pretargeted PCOS and of tumor imaging in vivo. These results suggested that 18F-FBB should be useful for pretargeted imaging with the (strept)avidin-Biotin system.
Hidekazu Kawashima - One of the best experts on this subject based on the ideXlab platform.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors. We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-18F-fluorobenzoyl)norBiotinamide (18F-FBB), a radiolabeled Biotin Derivative, for performing a biodistribution study and for PET imaging. The tumoral 18F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal. 18F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral 18F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing 18F-FBB accumulation corresponded to HIF-1α-positive areas. Pretargeting with POS and 18F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.
-
pet imaging of hypoxia inducible factor 1 active tumor cells with pretargeted oxygen dependent degradable streptavidin and a novel 18 f labeled Biotin Derivative
Molecular Imaging and Biology, 2011Co-Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae KizakakondohAbstract:Purpose We aimed to evaluate the feasibility of using streptavidin–Biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors.
-
synthesis and biological evaluation of a novel 18f labeled Biotin Derivative for strept avidin based pretargeted diagnosis
The Journal of Nuclear Medicine, 2008Co-Authors: Masashi Ueda, Takashi Kudo, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Hideo SajiAbstract:1259 Objectives: (Strept)avidin-Biotin based multistep targeting holds great promise for the detection and therapy of cancer. We have generated a streptavidin analogue, PCOS, for tumor hypoxia imaging (JNM48, Suppl.2, 21P). A radiolabeled Biotin Derivative is necessary to image with PCOS. For this purpose, we synthesized (4-[18F]fluorobenzoyl)norBiotinamide (18F-FBB), a novel 18F-labeled Biotin, and evaluated its suitability for pretargeted imaging. Methods: Radiosynthesis of 18F-FBB was performed by the conjugation of norBiotinamine and N-succinimidyl-4-[18F]fluorobenzoate. We prepared PCOS and the binding of 18F-FBB to avidin or PCOS was assessed. The stability of 18F-FBB in mouse plasma was checked by paper chromatography. Biodistribution study and small-animal PET imaging was performed in tumor-bearing mice with PCOS pretargeting 24 h prior to 18F-FBB injection. Results: The decay-corrected radiochemical yield of 18F-FBB was 23% with about 150-min reaction time and the radiochemical purity was greater than 95%. 18F-FBB showed binding affinity to avidin or PCOS. More than 91% of 18F-FBB was stable in mouse plasma for 6 h. 18F-FBB alone cleared quickly from the blood with no evidence of tumor targeting (0.06 %ID/g at 6 h), but when pretargeted with PCOS, tumor uptake increased 67-fold (4.0 %ID/g at 6 h) and the tumor was clearly visualized within 3 h. Conclusions: 18F-FBB exhibited not only an affinity to (strept)avidin in vitro, but it was also capable of binding to pretargeted PCOS and of tumor imaging in vivo. These results suggested that 18F-FBB should be useful for pretargeted imaging with the (strept)avidin-Biotin system.